Legal Status Overview
RestrictedPeptides are restricted in Nevada through a combination of federal FDA compounding law and Nevada State Board of Pharmacy enforcement rather than through any peptide-specific state statute. The Nevada Board of Pharmacy has issued formal declaratory-order notices directing 503A and 503B compounding pharmacies to stop compounding semaglutide and tirzepatide injection products once the FDA removed those drugs from its national shortage list. Research-use-only peptides such as BPC-157 and TB-500 are not named in any Nevada code but fall under general federal drug-approval and compounding law, which bars marketing or selling them for human consumption, and the Board has already taken enforcement action against unlicensed peptide distribution at a Las Vegas event. Nevada has no legislation that creates a distinct legal category for 'research chemicals' or peptides generally; licensed access runs through a prescribing practitioner and a 503A/503B pharmacy subject to Board of Pharmacy compounding rules.
Key Points
- Nevada has no statute or administrative code provision that names 'peptides' or 'research chemicals' as a distinct legal category; peptide products are instead governed by general FDA drug-approval law and Nevada's pharmacy compounding regulations under NAC 639.757. [5]
- The Nevada State Board of Pharmacy notified all licensees on June 2, 2025 that 503A compounding pharmacies must immediately stop compounding, distributing, or dispensing compounded tirzepatide and semaglutide injection products after the FDA removed both drugs from its federal shortage list. [1]
- Nevada 503B outsourcing facilities were directed to stop compounding, distributing, and dispensing compounded semaglutide injection products after May 22, 2025, per the Board of Pharmacy's notice implementing the FDA's February 2025 declaratory order. [1]
- Selling research-use-only peptides such as BPC-157 in Nevada is treated as legal only when genuinely marketed and labeled 'not for human consumption' for laboratory research, while selling or administering them for human use without FDA approval can trigger civil and criminal exposure under the federal Food, Drug and Cosmetic Act. [2]
- The Nevada State Board of Pharmacy fined three individuals, including a physician, for unlicensed wholesaling of peptide drugs after two women were hospitalized following peptide injections administered at a Las Vegas anti-aging conference booth. [3]
- A person cannot legally buy or personally bring compounded semaglutide, tirzepatide, or unapproved research peptides into Nevada for self-use outside a valid prescription and a licensed 503A/503B pharmacy or practitioner relationship, since the Board of Pharmacy treats unlicensed distribution of these products as a wholesaling and compounding violation under NRS 639.2895. [1]
- The Nevada State Board of Pharmacy is actively investigating multiple complaints about products marketed as 'semaglutide' for weight loss that may not contain the FDA-approved active ingredient, working jointly with the FDA to verify product legitimacy. [6]
- No Nevada-specific bill from the 2023-2025 legislative sessions was found that creates a standalone peptide or research-chemical statute; the state's recent regulatory activity on peptides has come entirely through Board of Pharmacy declaratory-order notices and amended compounding regulations (LCB File No. R053-24), not new legislation. [1]
Peptide-by-peptide status in Nevada
| BPC-157 | BPC-157 is not FDA-approved and is currently barred from pharmacy compounding as a 'Substance with Safety Concerns,' so in Nevada it can only be sold lawfully as a labeled research-use-only chemical, not for human administration by clinics or compounding pharmacies. [8] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | FDA-approved semaglutide and tirzepatide brand products remain legal in Nevada by prescription only, but Nevada compounding pharmacies (both 503A and 503B) have been directed by the Nevada State Board of Pharmacy to stop compounding injectable versions of these drugs since mid-2025 because the FDA removed them from its drug shortage list. [1] |
| TB-500 | TB-500 has no FDA approval and no Nevada-specific statute addressing it, so it falls into the same unapproved 'research chemical' category as BPC-157, legal to sell only for labeled non-human research use and not for human injection by clinics in Nevada. [2] |
| HGH / Somatropin | Human growth hormone (somatropin) is an FDA-approved prescription drug in Nevada, and distributing or possessing it without a valid prescription is restricted under general federal and state controlled-prescription-drug law rather than any peptide-specific Nevada statute. |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides like BPC-157 in Nevada without a prescription?
Unapproved research peptides such as BPC-157 can be purchased in Nevada only when sold and labeled as 'not for human consumption' research chemicals; selling or using them for human injection without a prescription falls outside the Nevada research-chemical carve-out and risks federal and state enforcement. [2]
Is it legal to get compounded semaglutide or tirzepatide in Nevada in 2026?
No, Nevada compounding pharmacies are currently barred from compounding, distributing, or dispensing semaglutide and tirzepatide injection products because the Nevada State Board of Pharmacy implemented FDA declaratory orders removing both drugs from the federal shortage list in 2025; only the FDA-approved brand-name versions remain available by prescription. [1]
Can a telehealth doctor prescribe peptides to me in Nevada?
A Nevada-licensed practitioner can prescribe FDA-approved peptide drugs (like approved semaglutide/tirzepatide or somatropin) through telehealth, but they cannot lawfully have a compounding pharmacy fill a compounded semaglutide or tirzepatide injection order now that the Board of Pharmacy has prohibited that compounding, and prescribing unapproved research peptides for human use is not a recognized lawful pathway. [1]
What happened with the Las Vegas peptide injection case and what penalties resulted?
After two women became critically ill from peptide injections given at a Las Vegas anti-aging conference booth, the Nevada State Board of Pharmacy fined three people involved, citing one supplier for unlicensed wholesaling of drugs for mailing peptides to the event. [3]
Does Nevada have its own law specifically regulating 'research chemicals' or peptides?
No, Nevada has no statute or administrative code that specifically names peptides or research chemicals as their own legal category; peptide products in Nevada are instead governed by the general federal Food, Drug and Cosmetic Act framework and the Nevada Board of Pharmacy's compounding rules under NAC 639.757. [5]